Merck & Co vows changes after falling foul of Japan's FTC
This article was originally published in Scrip
MSD (Merck & Co) in Japan is taking steps to address fair competition concerns that have been raised in a second warning from the country's Fair Trade Commission in relation to certain educational and promotional activities conducted by the subsidiary over the 2009-10 period.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.